Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Filip Janku Sells 6,000 Shares of Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Filip Janku sold 6,000 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $22.95, for a total transaction of $137,700.00. Following the completion of the transaction, the insider owned 59,992 shares in the company, valued at approximately $1,376,816.40. This trade represents a 9.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Filip Janku also recently made the following trade(s):

• On Tuesday, June 23rd, Filip Janku sold 11,845 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $20.22, for a total transaction of $239,505.90.
• On Wednesday, June 24th, Filip Janku sold 30,000 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $21.42, for a total transaction of $642,600.00.

Monte Rosa Therapeutics Price Performance

NASDAQ GLUE opened at $24.20 on Wednesday. The firm has a market cap of $2.04 billion, a PE ratio of -16.35 and a beta of 1.60. Monte Rosa Therapeutics, Inc. has a one year low of $4.12 and a one year high of $25.77. The stock’s 50 day simple moving average is $19.15 and its 200 day simple moving average is $18.74.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The business had revenue of $4.21 million during the quarter, compared to the consensus estimate of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. As a group, equities analysts expect that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Wells Fargo & Company decreased their price target on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, March 18th. Weiss Ratings raised shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. JPMorgan Chase & Co. lifted their target price on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Guggenheim upped their target price on shares of Monte Rosa Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Wall Street Zen downgraded Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.33.

Institutional Trading of Monte Rosa Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC acquired a new stake in shares of Monte Rosa Therapeutics in the 4th quarter valued at approximately $30,000. Russell Investments Group Ltd. acquired a new position in Monte Rosa Therapeutics during the third quarter valued at approximately $32,000. Lazard Asset Management LLC grew its holdings in Monte Rosa Therapeutics by 42.9% during the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock valued at $48,000 after purchasing an additional 3,262 shares during the period. Nisa Investment Advisors LLC increased its stake in Monte Rosa Therapeutics by 16.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock valued at $49,000 after purchasing an additional 451 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Monte Rosa Therapeutics by 32.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after purchasing an additional 776 shares in the last quarter. 79.96% of the stock is owned by institutional investors.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.